Is mirtazapine appropriate for treating insomnia and reducing stimulant cravings in an adult patient?

Mirtazapine is NOT Recommended for Insomnia Based on Current Guidelines, and Evidence for Stimulant Cravings is Preliminary

Mirtazapine should not be used as a treatment for chronic insomnia in adults, as it is explicitly not recommended by the American Academy of Sleep Medicine (AASM) 2017 guidelines. While emerging research shows promise for both sleep and stimulant cravings, guideline-based alternatives exist for insomnia, and evidence for treating stimulant cravings remains limited.

For Insomnia: Use Guideline-Recommended Agents Instead

First-Line Approach

• Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first-line treatment for chronic insomnia disorder in adults 1
• CBT-I shows moderate-quality evidence for improving sleep onset latency, wake after sleep onset, sleep efficiency, and overall sleep quality 1

When Pharmacotherapy is Needed

If CBT-I alone fails, the AASM guidelines 2 recommend these FDA-approved options:

For Sleep Onset Insomnia:

• Zolpidem 10 mg
• Zaleplon 10 mg
• Ramelteon 8 mg
• Triazolam 0.25 mg
• Eszopiclone 2-3 mg
• Temazepam 15 mg

For Sleep Maintenance Insomnia:

• Suvorexant 10-20 mg
• Doxepin 3-6 mg
• Eszopiclone 2-3 mg
• Zolpidem 10 mg
• Temazepam 15 mg

Why Mirtazapine is Not Recommended

The AASM explicitly recommends AGAINST using trazodone for insomnia 2, and mirtazapine is not mentioned in their guideline recommendations at all—meaning it lacks sufficient evidence for this indication. The FDA label confirms mirtazapine is only indicated for major depressive disorder 3, not insomnia.

The Research-Guideline Gap

Despite guideline recommendations against off-label use, recent research shows:

• A 2025 RCT in older adults (≥65 years) found mirtazapine 7.5 mg significantly reduced Insomnia Severity Index scores (-6.5 vs -2.9 for placebo, p=0.003) 4
• However, 6 of 30 patients (20%) discontinued due to adverse events 4
• A 2026 retrospective study of ultra-low-dose mirtazapine (3.75 mg) showed 47% of veterans had meaningful ISI improvement 5
• A 2017 RCT found 7.5 mg mirtazapine increased total sleep time by 30 minutes but caused daytime sleepiness and reduced sustained attention 6

The critical issue: These studies are too recent to have influenced the 2017 AASM guidelines, and no major guideline update has incorporated this data. Until guidelines are revised, use FDA-approved agents with established safety profiles 1, 2.

Common Pitfalls

• Weight gain and increased appetite are very common with mirtazapine (>10% incidence) 3, 7, 4
• Next-day sedation impairs alertness and cognitive function 6
• Serotonin syndrome risk when combined with other serotonergic agents 3
• Pharmacotherapy should be short-term only (4-5 weeks) per FDA guidance 1

For Stimulant Cravings: Evidence is Emerging but Limited

Current Evidence

A 2026 systematic review 8 examining pharmacological treatments for sleep disturbances in cocaine use disorder (CUD) and methamphetamine use disorder (MUD) found:

For Cocaine Use Disorder:

• Modafinil, buprenorphine, and suvorexant showed preliminary improvements in sleep parameters
• Modafinil was linked to higher abstinence rates
• Mirtazapine results were mixed 8

For Methamphetamine Use Disorder:

• Mirtazapine demonstrated modest initial benefits 8
• Modafinil also showed preliminary promise
• Quetiapine and suvorexant had limited data from small studies

Case Report Evidence

A 2022 case report 9 described a 71-year-old man with benzodiazepine dependence where mirtazapine was effective for both sleep disturbance and BZD cravings. The proposed mechanism involves increased dopamine, norepinephrine, and serotonin signaling 9. However, a single case report cannot establish treatment efficacy.

Clinical Reality

The evidence for mirtazapine treating stimulant cravings is insufficient to make a firm recommendation. The 2026 systematic review 8 concluded that pharmacological interventions showed "emerging but inconsistent benefits" due to small sample sizes, short treatment durations, and methodological limitations.

Practical Algorithm

If the patient has insomnia WITHOUT stimulant use disorder:

1. Start with CBT-I
2. If CBT-I fails, use guideline-recommended agents (zolpidem, eszopiclone, suvorexant, or doxepin depending on sleep onset vs. maintenance pattern)
3. Avoid mirtazapine unless treating comorbid major depressive disorder 3

If the patient has insomnia WITH active stimulant use disorder:

1. Address the substance use disorder as primary treatment
2. For insomnia, still prioritize CBT-I and guideline-recommended agents
3. Consider mirtazapine only if:
   • Comorbid major depression is present (FDA-approved indication) 3
   • Patient has failed multiple guideline-recommended agents
   • Benefits of potential craving reduction outweigh risks of weight gain, sedation, and lack of guideline support
4. Monitor closely for adverse effects, particularly weight gain, daytime sedation, and drug interactions 3

If the patient has stimulant cravings WITHOUT significant insomnia:

• Mirtazapine lacks sufficient evidence for this indication alone
• Focus on evidence-based addiction treatment modalities

Safety Monitoring

When mirtazapine is used (for its FDA-approved indication of depression), monitor for:

• Suicidal ideation (black box warning) 3
• Weight gain and metabolic changes (cholesterol, triglycerides) 3
• Low white blood cell count (agranulocytosis risk) 3
• QT prolongation if cardiac risk factors present 3
• Discontinuation syndrome if stopped abruptly 3